{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T20:36:43Z","timestamp":1788640603564,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T00:00:00Z","timestamp":1334188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00066-012-0096-1","type":"journal-article","created":{"date-parts":[[2012,4,11]],"date-time":"2012-04-11T06:30:10Z","timestamp":1334125810000},"page":"518-522","source":"Crossref","is-referenced-by-count":13,"title":["Relapsing high grade mucoepidermoid carcinoma","Rezidiviertes hochgradiges Mukoepidermoidkarzinom"],"prefix":"10.1007","volume":"188","author":[{"given":"D.","family":"Milanovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Jeremic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.","family":"Rischke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Henke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,12]]},"reference":[{"key":"96_CR1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","volume":"11","author":"Bonner","year":"2010","unstructured":"Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21\u201328","journal-title":"Lancet Oncol"},{"key":"96_CR2","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1200\/jco.2010.28.15_suppl.5557","volume":"28","author":"Brohl","year":"2010","unstructured":"Brohl A, Steadman K, Kallakury B, Deeken JF (2010) Efficacy of combining targeted therapies cetuximab and dasatinib for resistant salivary gland carcinomas in vitro. J Clin Oncol 28:15S (abstr 5557)","journal-title":"J Clin Oncol"},{"key":"96_CR3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00066-005-1319-5","volume":"181","author":"Burdak-Rothkamm","year":"2005","unstructured":"Burdak-Rothkamm S, R\u00fcbe CE, Nguyen TP et al (2005) Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa). Strahlenther Onkol 181:197\u2013204","journal-title":"Strahlenther Onkol"},{"key":"96_CR4","first-page":"854","volume":"60","author":"Buerger","year":"2000","unstructured":"Buerger H, Gebhardt F, Schmidt H et al (2000) Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 60:854\u2013857","journal-title":"Cancer Res"},{"key":"96_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00066-009-2026-4","volume":"186","author":"Dittmann","year":"2010","unstructured":"Dittmann K, Mayer C, Rodemann HP (2010) Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. Strahlenther Onkol 186:1\u20136","journal-title":"Strahlenther Onkol"},{"key":"96_CR6","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/hed.21312","volume":"32","author":"Erovic","year":"2010","unstructured":"Erovic BM, Schopper C, Pammer J et al (2010) Multimodal treatment of patients with minor salivary gland cancer in the case of recurrent disease. Head Neck 32:1167\u20131172","journal-title":"Head Neck"},{"key":"96_CR7","first-page":"929","volume":"15","author":"Gebhardt","year":"2000","unstructured":"Gebhardt F, B\u00fcrger H, Brandt B (2000) Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations\u2014a link between genetics and epigenetics. Histol Histopathol 15:929\u2013936","journal-title":"Histol Histopathol"},{"key":"96_CR8","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/00005537-200108000-00011","volume":"111","author":"Gibbons","year":"2001","unstructured":"Gibbons MD, Manne U, Carroll WR et al (2001) Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 111:1373\u20131378","journal-title":"Laryngoscope"},{"key":"96_CR9","doi-asserted-by":"crossref","first-page":"580S","DOI":"10.1200\/jco.2005.23.16_suppl.580","volume":"23","author":"Glisson","year":"2005","unstructured":"Glisson BS, Blumenschein G, Francisco M et al (2005) Phase II trial of gefitinib in patients with incurable salivary gland cancer. J Clin Oncol 23:580S (abstr 5532)","journal-title":"J Clin Oncol"},{"key":"96_CR10","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1217::AID-CNCR2>3.0.CO;2-C","volume":"82","author":"Goode","year":"1998","unstructured":"Goode RK, Auclair PL, Ellis GL (1998) Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer 82:1217\u20131224","journal-title":"Cancer"},{"key":"96_CR11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/1752-1947-2-320","volume":"30","author":"Grisanti","year":"2008","unstructured":"Grisanti S, Amoroso V, Buglione M et al (2008) Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature. J Med Case Reports 30:320","journal-title":"J Med Case Reports"},{"key":"96_CR12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.critrevonc.2009.10.004","volume":"74","author":"Guzzo","year":"2010","unstructured":"Guzzo M, Locati LD, Prott FJ et al (2010) Major and minor salivary gland tumors. Crit Rev Oncol Hematol 74:134\u2013148","journal-title":"Crit Rev Oncol Hematol"},{"key":"96_CR13","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.ijrobp.2011.01.004","volume":"81","author":"Hoebers","year":"2011","unstructured":"Hoebers F, Heemsbergen W, Moor S et al (2011) Reirradiation for head-and-neck cancer: delicate balance between effectiveness and toxicity. Int J Radiat Oncol Biol Phys 81:e111\u2013118","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"96_CR14","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.2005.05.3025","volume":"24","author":"Laurie","year":"2006","unstructured":"Laurie SA, Licitra L (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24:2673\u20132678","journal-title":"J Clin Oncol"},{"key":"96_CR15","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/annonc\/mdq588","volume":"22","author":"Licitra","year":"2011","unstructured":"Licitra L, Mesia R, Rivera F et al (2011) Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and\/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 22:1078\u20131087","journal-title":"Ann Oncol"},{"key":"96_CR16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.oraloncology.2008.07.010","volume":"45","author":"Locati","year":"2009","unstructured":"Locati LD, Bossi P, Perrone F et al (2009) Cetuximab in recurrent and\/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45:574\u2013578","journal-title":"Oral Oncol"},{"key":"96_CR17","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/sj.bjc.6605788","volume":"103","author":"Lujan","year":"2010","unstructured":"Lujan B, Hakim S, Moyano S et al (2010) Activation of the EGFR\/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 103:510\u2013516","journal-title":"Br J Cancer"},{"key":"96_CR18","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129\u20132139","journal-title":"N Engl J Med"},{"key":"96_CR19","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ijrobp.2003.08.035","volume":"58","author":"Milas","year":"2004","unstructured":"Milas L, Fan Z, Andratschke NH, Ang KK (2004) Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 58:966\u2013971","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"96_CR20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0714.2009.00770.x","volume":"38","author":"Monteiro","year":"2009","unstructured":"Monteiro LS, Bento MJ, Palmeira C et al (2009) Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours. J Oral Pathol Med 38:508\u2013513","journal-title":"J Oral Pathol Med"},{"key":"96_CR21","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/cncr.23825","volume":"113","author":"Nance","year":"2008","unstructured":"Nance MA, Seethala RR, Wang Y et al (2008) Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma. Cancer 113:2082\u20132089","journal-title":"Cancer"},{"key":"96_CR22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00066-009-2092-7","volume":"185","author":"Balermpas","year":"2009","unstructured":"Balermpas P, Hambek M, Seitz O et al (2009) Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. Strahlenther Onkol 185:775\u2013781","journal-title":"Strahlenther Onkol"},{"key":"96_CR23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00066-010-2139-9","volume":"187","author":"Platteaux","year":"2011","unstructured":"Platteaux N, Dirix P, Vanstraelen B et al (2011) Outcome after re-irradiation of head and neck cancer patients. Strahlenther Onkol 187:23\u201331","journal-title":"Strahlenther Onkol"},{"key":"96_CR24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/PAP.0b013e318202645a","volume":"18","author":"Seethala","year":"2011","unstructured":"Seethala RR (2011) Histologic grading and prognostic biomarkers in salivary gland carcinomas. Adv Anat Pathol 18:29\u201345","journal-title":"Adv Anat Pathol"},{"key":"96_CR25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00066-011-2217-7","volume":"187","author":"Selzer","year":"2011","unstructured":"Selzer E, Liederer S, Lemaire C et al (2011) Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab. Strahlenther Onkol 187:373\u2013377","journal-title":"Strahlenther Onkol"},{"key":"96_CR26","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.3800946","volume":"20","author":"Sholl","year":"2007","unstructured":"Sholl LM, John Iafrate A, Chou YP et al (2007) Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol 20:1028\u20131035","journal-title":"Mod Pathol"},{"key":"96_CR27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1056\/NEJM200507143530218","volume":"353","author":"Tsuchihashi","year":"2005","unstructured":"Tsuchihashi Z, Khambata-Ford S, Hanna N et al (2005) Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 353:208\u2013209","journal-title":"N Engl J Med"},{"key":"96_CR28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00066-010-2149-7","volume":"187","author":"Zwicker","year":"2011","unstructured":"Zwicker F, Roeder F, Thieke C et al (2011) IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol 187:32\u201338","journal-title":"Strahlenther Onkol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-012-0096-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-012-0096-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-012-0096-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T02:31:05Z","timestamp":1558578665000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-012-0096-1"}},"subtitle":["Long-lasting complete response following reirradiation and EGFR blockade","Anhaltende komplette Remission nach Rebestrahlung und EGFR-Inhibition"],"short-title":[],"issued":{"date-parts":[[2012,4,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["96"],"URL":"https:\/\/doi.org\/10.1007\/s00066-012-0096-1","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,12]]}}}